4.7 Article

The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database

Journal

JOURNAL OF TRANSLATIONAL MEDICINE
Volume 17, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12967-019-2069-y

Keywords

Breast neoplasms; Metaplastic breast cancer; Radiotherapy; Prognosis; Survival

Funding

  1. National Institutes of Health (NIH/NCATS) through the NIH Common Fund, Office of Strategic Coordination (OSC) [UH3TR00943-01]
  2. NCI [1R01 CA182905-01, 1R01CA222007-01A1]
  3. NIGMS [1R01GM122775-01]
  4. U54 Grant-UPR/MDACC Partnership for Excellence in Cancer Research 2016 Pilot Project
  5. Team DOD [CA160445P1]
  6. Ladies Leukemia League Grant
  7. CLL Moonshot Flagship project
  8. SINF 2017 Grant
  9. POC Grant [35/01.09.2016]
  10. Natural Science Foundation of Zhejiang Province [LQ17H160013]
  11. Zhejiang Province Health Department Foundation [2018ky284]
  12. National Natural Science Foundation of China [81601899]
  13. Fulbright Research Scholarship (year 2018)
  14. Estate of C. G. Johnson

Ask authors/readers for more resources

Background: Only few studies, with small patient cohorts, have evaluated the effect of radiotherapy (RT) for metaplastic breast cancer (MBC). Hence, it is important to investigate the role of RT in MBC survival using a large population-database. Methods: A retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) from 1973 to 2015 was performed. We compared MBC patients with or without RT for overall survival (OS) and breast cancer-specific survival (BCSS) using univariate and multivariate Cox proportional hazard regressions before and after propensity score matching (PSM). Results: From a total of 2267 patients diagnosed with MBC between 1998 and 2015, 1086 (47.9%) received RT. In the multivariate analysis before PSM, RT provided a better OS (HR 0.73; 95% CI 0.61-0.88; p = 0.001) and BCSS (HR 0.71; 95% CI 0.58-0.88; p = 0.002). Multivariate analyses after PSM (n = 1066) confirmed that patients receiving RT (n = 506) survived longer than those without RT (OS, HR 0.64; 95% CI 0.51-0.80; p < 0.001 and BCSS, HR 0.64; 95% CI 0.50-0.83; p = 0.001). A longer OS was observed when RT was given to older patients (p = 0.001) and in case of large tumor size (p = 0.002). Intriguingly, patients with N0 stage showed better OS after RT (HR 0.69, P = 0.012). Conclusions: Our findings support the beneficial effect of RT for MBC patients. In particular, older patients or with large tumor size have a greater survival benefit from RT. In conclusion, we have assessed the importance of the use of RT in MBC as survival factor and this could lead to the development of guidelines for this rare sub-type of tumors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available